TC Home

The only technical publication dedicated to readers who formulate, manufacture, or package solid dosage forms.

Slide background
Slide background
Slide background
  • June 26, 2019

SILVER SPRING, MD–The agency approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) to treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These drug products are the first FDA-approved treatments for ATTR-CM. They are manufactured by FoldRx, a subsidiary of Pfizer, New York, NY.